The genetic association of miR-34a-5p rs72631823 with the susceptibility to obstetric antiphospholipid syndrome.

Researchers investigated a genetic variant that may help explain why some pregnant women develop obstetric antiphospholipid syndrome (OAPS), a serious autoimmune condition that increases risks during pregnancy. The study examined 182 women with OAPS and 188 healthy pregnant women, focusing on a specific genetic change (rs72631823) that affects a molecule called miR-34a-5p. They found that women carrying the AA version of this genetic variant had three times the risk of developing OAPS compared to those with the GG version. This genetic change also increased miR-34a-5p levels in the blood, which correlated with worse outcomes for both mothers and babies. Women with the AA genotype had nearly four times higher risk of poor maternal outcomes and three times higher risk of poor infant outcomes. The miR-34a-5p molecule showed promise as a diagnostic marker, correctly identifying OAPS in about 79% of cases. Computer analysis suggested this molecule affects inflammatory and blood clotting pathways, which could explain its role in OAPS. While this study doesn't directly address acupuncture treatment, understanding the biological mechanisms behind OAPS may help integrate complementary therapies more effectively. Women with autoimmune conditions often seek acupuncture as an adjunct therapy to help manage inflammation and improve pregnancy outcomes, though more research is needed specifically for OAPS. Patients interested in acupuncture should work with a licensed acupuncturist experienced in treating autoimmune conditions and pregnancy-related health concerns.

This case-control study (n=182 OAPS patients, n=188 controls) examined the association between pre-miR-34a rs72631823 polymorphism and obstetric antiphospholipid syndrome susceptibility. Using TaqMan genotyping and RT-qPCR, researchers found the AA genotype independently associated with increased OAPS risk (adjusted OR=3.002, 95% CI=1.189-7.581, P=0.020) with dose-dependent effects on miR-34a-5p expression. The variant predicted poor maternal outcomes (AA vs. GG: adjusted OR=3.767, 95% CI=1.419-10.003, P=0.008) and infant outcomes (AA vs. GG: adjusted OR=2.957, 95% CI=1.059-8.258, P=0.039). Diagnostic performance showed strong discriminative ability (AUC=0.859, sensitivity=79.12%, specificity=77.66%). Bioinformatics analysis implicated Wnt signaling, MAPK pathway, and vascular development as potential mechanistic targets. Clinical relevance: elevated miR-34a-5p expression may serve as both a prognostic biomarker and therapeutic target for OAPS, with implications for integrating anti-inflammatory approaches in treatment protocols.